This research highlights a major advancement in computational drug discovery. By applying an AI-driven screening method to a virtual database of over 37 billion chemical compounds, our team identified 124 novel drug candidates with high potential to inhibit HIV replication. This breakthrough dramatically reduces the time and cost typically required for early-stage drug discovery.
The project combines molecular docking, pharmacokinetics modeling, and machine learning to filter vast datasets with precision. The identified compounds are now being prioritized for preclinical validation in collaboration with academic and clinical partners across Africa and Europe.
This AI pipeline demonstrates how large-scale, data-driven approaches can bring hope for faster and more affordable treatment options for HIV – a disease still highly prevalent in sub-Saharan Africa. It also reinforces the role of artificial intelligence in democratizing pharmaceutical innovation and tackling global health challenges.
